Mobilizing antitumour immunity through vaccination potentially constitutes a powerful
anticancer strategy but has not yet provided robust clinical benefits in large patient …

A fundamental prerequisite for the efficacy of cancer immunotherapy is the presence of
functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a …

DNA mismatch repair deficiency (MMRd) is associated with a high tumor mutational burden
(TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most …

Neoantigens are peptides derived from non-synonymous mutations presented by human
leukocyte antigens (HLAs), which are recognized by antitumour T cells,,,,,,,,,,,,–. The large …

Although patients with microsatellite instable metastatic colorectal cancer (CRC) benefit from
immune checkpoint blockade, chemotherapy with targeted therapies remains the only …

Thousands of genetic variants in protein-coding genes have been linked to disease.
However, the functional impact of most variants is unknown as they occur within intrinsically …

The CD155/TIGIT axis can be co-opted during immune evasion in chronic viral infections
and cancer. Pancreatic adenocarcinoma (PDAC) is a highly lethal malignancy, and immune …

Fewer than half of all patients with advanced-stage high-grade serous ovarian cancers
(HGSCs) survive more than five years after diagnosis, but those who have an exceptionally …

Neoantigens generated by somatic nonsynonymous mutations are key targets of tumor-
specific T cells, but only a small number of mutations predicted to be immunogenic are …

The accurate selection of neoantigens that bind to class I human leukocyte antigen (HLA)
and are recognized by autologous T cells is a crucial step in many cancer immunotherapy …